Synektik to reach almost PLN 100m in revenues in 2013

2011-12-21



Synektik expects group revenues to surge by between 70-90% in 2012 to exceed PLN 77m (€17.1m), thanks chiefly to a new revenue stream from PET pharmaceuticals, the company says in an updated financial forecast for 2012-2013, published on 20 December 2011. In 2013 sales growth is projected to come in at 26%, to PLN 97m (€21.6m).
The NewConnect-listed diagnostic imaging solutions provider also expects a substantial improvement in profits during this period, with group net profit forecast to reach almost PLN 7.75m (€1.72m) next year and PLN 14.37m (€3.19m) in 2013.
For 2011 Synektik is projecting sales of PLN 40-45m (€8.9-10m). No estimate of group net profit for this year was given. By way of comparison, in 2010 the company earned a net profit of PLN 1.3m (€0.29m) on sales of PLN 31m (€6.9m).
The revised financial forecast is predicated on Iason, the radiopharmaceuticals unit, meeting a growing part of demand for PET pharmaceuticals generated by PET-CT clinics in Poland; an expansion of the group’s equipment servicing business to include X-ray devices; further growth in scale at its diagnostic equipment delivery unit; and revenues from servicing of IT solutions.
See also the news item "Synektik announces multimillion radiopharmaceuticals contracts with Euromedic".